Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer.

Yinu Wang Xiaolei Situ Horacio Cardenas Ellie Siu Sayedabdulrazzaq A Alhunayan Russell Keathley Edward J Tanner Jian-Jun Wei Yuying Tan Chinmayee Vallabh Prabhu Dessai Ji-Xin Cheng Daniela E Matei

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

NTX-301 is active in ovarian cancer models. Our findings point to a new mechanism by which epigenetic blockade disrupts lipid homeostasis and promotes cancer cell death.

Keyphrases

cell death
papillary thyroid
dna methylation
circulating tumor
gene expression
squamous cell
cell free
cell therapy
stem cells
lymph node metastasis
mesenchymal stem cells
young adults
childhood cancer